Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cangene shares defence costs for Nucleic Acid Sequence Based Amplification (NASBA):

This article was originally published in Clinica

Executive Summary

Canadian pharmaceutical company Cangene has agreed to escrow Can$1 million as its share of the defence costs of a threatened legal action by Roche against Akzo. The action has been brought against Akzo's HIV kits which utilise Cangene's NASBA technology (see Clinica No 674, p 13). "This resolution recognises that while Roche filed against Akzo after they had signed the NASBA sale agreement, Cangene has some obligation to assist Akzo in dealing with it," says Cangene's CEO James Rae.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093579

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel